Alternatively, it is possible that GLP-1 adjunctive therapy in T1DM patients exerts its beneficial effects directly via extrapancreatic target organs other than the stomach or indirectly via the central nervous system [35]. The gene discussed is GCG; the disease is type 1 diabetes mellitus.